Enfermedad de Fabry Enfermedad de Fabry - Sociedad Argentina ...
Enfermedad de Fabry Enfermedad de Fabry - Sociedad Argentina ...
Enfermedad de Fabry Enfermedad de Fabry - Sociedad Argentina ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
XIII. Bibliografía<br />
1. Argoff CE, Barton NW, Brady RO, Ziesmann HA. Gastrointestinal<br />
symptoms and <strong>de</strong>layed gastric emptying in <strong>Fabry</strong>’s disease: Response to<br />
metocloprami<strong>de</strong>. Nucl Med Commun 1998; 19: 887-891.<br />
2. Alroy J, Sabnis S, Kopp JB. Renal pathology in <strong>Fabry</strong> disease. J Am Soc<br />
Nephrol. 2002;13 Suppl 2:S134-8.<br />
3. Banikazemi M, Bultas J, Wal<strong>de</strong>k S, Wilcox WR, Whitley CB,<br />
McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ;<br />
<strong>Fabry</strong> Disease Clinical Trial Study Group. Agalsidase-beta therapy for<br />
advanced <strong>Fabry</strong> disease: a randomized trial. Ann Intern Med. 2007 Jan<br />
16;146(2):77-86.<br />
4. Bennett RL, Hart KA, Rourke EO, Barranger JA, Jonson J, MacDermont KD,<br />
Pastores GM, Steiner RD, Thadhani R. <strong>Fabry</strong> disease in genetic counselling<br />
practice: recommendations of the national society of genetic counsellors. J<br />
Genet Counsel 2002; 11: 121-146.<br />
5. Bierer G, Kamangar N, Balfe D, Wilcox WR, Mosenifar Z. Cardiopulmonary<br />
Exercise Testing in <strong>Fabry</strong> Disease. Respiration 2005;72:504–511<br />
6. Birklein F. Mechanisms of neurophatic pain and their importance in <strong>Fabry</strong><br />
disease. Acta Paediatr Suppl 2002; 439: 34-37.<br />
7. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L.<br />
Enzymatic <strong>de</strong>fect in <strong>Fabry</strong>´s disease. Cerami<strong>de</strong>trihexosidase <strong>de</strong>ficiency. N<br />
Engl J Med. 1976; 276: 1163-1167.<br />
8. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal<br />
involvement in <strong>Fabry</strong> disease. J Am Soc Nephrol. 2002;13 Suppl 2:S139-43.<br />
9. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu<br />
G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB. Natural history of<br />
<strong>Fabry</strong> renal disease: influence of alpha-galactosidase A activity and genetic<br />
mutations on clinical course. Medicine (Baltimore). 2002;8: 122-38.<br />
10. Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G,<br />
Eng CM, Desnick RJ. Pulmonary involvement in <strong>Fabry</strong> disease. Am J Respir<br />
Crit Care Med 1997; 155:1004-10<br />
11. Cable WJ, Kolodny EH, Adams RD. <strong>Fabry</strong> disease: impaired autonomic<br />
function. Neurology 1982; 32: 498-502.<br />
12. Chamoles NA, Blanco M, Gaggioli D. <strong>Fabry</strong> disease: enzymatic diagnosis<br />
in dried blood spots on filter paper. Clin Chim Acta 2001; 308: 195-196<br />
13. Chowdhury MM, Holt PJ. Pain in An<strong>de</strong>rson-<strong>Fabry</strong> disease. Lancet 2001;<br />
357: 887.<br />
14. Cleeland CS. Pain assessment: the adventages of using pain scales in<br />
lysosomal storage diseases. Acta Paediatr Suppl 2002; 439: 43-47.<br />
15. Clinical Practice Gui<strong>de</strong>lines for Chronic Kidney Disease: Evaluation,<br />
Classification, and Stratification. Part 4. Definition and classification of stages<br />
of chronic kidney disease. Am J Kidney Dis 39:S46-S75, 2002 (suppl 1).<br />
16. Clinical Practice Gui<strong>de</strong>lines for Chronic Kidney Disease: Evaluation,<br />
Classification, and Stratification Part 5. Evaluation of laboratory<br />
measurements for clinical assessment of kidney disease. Gui<strong>de</strong>line 4.<br />
Estimation of GFR . Disponible en http://www.kidney.org/professionals/KDOQI/<br />
gui<strong>de</strong>lines_ckd/toc.htm.<br />
17. Conti G, Sergi B. Auditory and vestibular findings in <strong>Fabry</strong> disease: a<br />
study of hemizygous males and heterozygous females. Acta Paediatr Suppl.<br />
2003;92:33-7.<br />
18. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W.<br />
<strong>Fabry</strong> disease: enzymatic diagnosis of hemizygotes and heterozygotes<br />
α-galactosidase activities in plasma, serum, urine and leukocytes. J Lab Clin<br />
Med 1973; 81: 157-171<br />
19. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A <strong>de</strong>ficiency: <strong>Fabry</strong><br />
disease. In: Scriver CR, Beau<strong>de</strong>t AL, Sly WS, Valle D, eds. The metabolic<br />
bases of Inherited Disease. 8th ed. New York: MacGraw-Hill; 2001: 3733-3774<br />
20. Desnick RJ, Brady RO, Barranger J, Collins AJ, Germain DP, Goldman M,<br />
Grabowsky GA, Packman S, Wilcox WR. <strong>Fabry</strong> Disease, an un<strong>de</strong>r-recognized<br />
multisystemic disor<strong>de</strong>r: expert recommendations for diagnosis, management<br />
and enzyme replacement therapy. Ann Intern Med 2003; 38: 338-346.<br />
21. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I,<br />
Reichek N. Ecocardiography assessment of left ventricular hypertrophy:<br />
comparison to necropsy findings. Am J of Cardiol 1986; 57:459-8<br />
22. De Schoenmakere G, Chauveau D, Grunfeld JP. Enzyme replacement<br />
therapy in An<strong>de</strong>rson-<strong>Fabry</strong>’s disease: beneficial clinical effect on vital organ<br />
function. Nephrol Dial Transplant. 2003 ;18:33-5.<br />
23. Dominguez RO, Amartino H, Chamoles NA, Grupo <strong>de</strong> Estudio <strong>de</strong> la<br />
<strong>Enfermedad</strong> <strong>de</strong> <strong>Fabry</strong> G. Neuropathic pain in <strong>Fabry</strong>’s disease: heterogeneous<br />
remission in three years of enzyme replacement therapy. Rev Neurol. 2006<br />
Aug 16-31;43:201-6.<br />
24. Dütsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz JM. Small fiber<br />
dysfunction predominates in <strong>Fabry</strong> neuropathy. J Clin Neuroph 2002; 19:<br />
575-586.<br />
25. Eng CM, Gurron N, Wilcox WR, Germain DP, Lee P, Wal<strong>de</strong>k S, et al. Safety<br />
and efficacy of recombinant human α-galactosidase A-replacement therapy in<br />
<strong>Fabry</strong>´s disease. N Engl J Med. 2001; 345:9-16.<br />
26. Eng CM, Fletcher J, Wilcox WR, Wal<strong>de</strong>k S, Scott CR, Sillence DO, Breunig<br />
F, Charrow J, Germain DP, Nicholls K, Banikazemi M. <strong>Fabry</strong> disease: baseline<br />
medical characteristics of a cohort of 1765 males and females in the <strong>Fabry</strong><br />
Registry. J Inherit Metab Dis. 2007 Apr;30(2):184-92<br />
27. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ,<br />
Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR.<br />
<strong>Fabry</strong> disease: gui<strong>de</strong>lines for the evaluation and management of multi-organ<br />
system involvement. Genet Med. 2006 ;8(9):539-48.<br />
28. Eto Y, Ohashi T, Utsunomiya Y, Fujiwara M, Mizuno A, Inui K, Sakai N,<br />
Kitagawa T, Suzuki Y, Mochizuki S, Kawakami M, Hosoya T, Owada M,<br />
Sakuraba H, Saito H. Enzyme replacement therapy in Japanese <strong>Fabry</strong><br />
disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis.<br />
2005;28:575-83.<br />
29. Fellgiebel A, Mazanek M, Whybra C, Beck M, Hartung R, Muller KM,<br />
Scheurich A, Dellani PR, Stoeter P, Muller MJ. Pattern of microstructural<br />
brain tissue alterations in <strong>Fabry</strong> disease A diffusion-tensor imaging study. J<br />
Neurol. 2006; 6: 1-8<br />
30. Filling-Katz MR, Merrick HF, Finf JC, Miles RB, Sokol J, Barton NW.<br />
Carbamacepine in <strong>Fabry</strong>’s disease: effective analgesia with dose-<strong>de</strong>pen<strong>de</strong>nt<br />
exacerbation of autonomic dysfunction. Neurology 1989; 39: 598-600.<br />
31. Germain DP, Wal<strong>de</strong>k S, Banikazemi M, Bushinsky DA, Charrow J,<br />
Desnick RJ, Lee P, Loew T, Ved<strong>de</strong>r AC, Abichandani R, Wilcox WR, Guffon<br />
N. Sustained, long-term renal stabilization after 54 months of agalsidase<br />
beta therapy in patients with <strong>Fabry</strong> disease. J Am Soc Nephrol. 2007<br />
May;18(5):1547-57.<br />
32. Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with <strong>Fabry</strong><br />
disease have an increased inci<strong>de</strong>nce of progressive hearing loss and sud<strong>de</strong>n<br />
<strong>de</strong>afness: an investigation of twenty-two hemizygous male patients. BMC<br />
Med Genet. 2002 ;3:1-10<br />
33. Glass RB, Astrin KH, Norton KI, Parsons R, Eng CM, Banikazemi M,<br />
Desnick RJ. <strong>Fabry</strong> disease: renal sonographic and magnetic resonance<br />
imaging findings in affected males and carrier females with the classic and<br />
cardiac variant phenotypes. J Comput Assist Tomogr. 2004 ;28:158-68.<br />
34. Gomez I, Nora DB, Becker J, Ehlers JAC, Schwartz IVD, Giugliani R, et al.<br />
Nerve conduction studies, electromyography and sympathetic skin response<br />
in <strong>Fabry</strong>’s disease. J Neurol Scien 2003; 214: 21-25.<br />
35. Gordon KE, Ludman MD, Finley GA. Succesful treatment of painful crises<br />
of <strong>Fabry</strong> disease with low dose morphine. Paediatr Neurol 1995; 12: 250-251.<br />
36. Grunfeld JP, Lidove O, Joly D, Barbey F. Renal disease in <strong>Fabry</strong> patients. J<br />
Inherit Metab Dis. 2001;24 Suppl 2:71-4.<br />
37. Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A.<br />
Hearing loss in <strong>Fabry</strong> disease: the effect of agalsidase alfa replacement<br />
therapy. J Inherit Metab Dis. 2003;26:787-94.<br />
38. Hegemann S, Hajioff D, Conti G, Beck M, Sun<strong>de</strong>r-Plassmann G, Widmer<br />
U, Mehta A, Keilmann A. Hearing loss in <strong>Fabry</strong> disease: data from the <strong>Fabry</strong><br />
Outcome Survey. 2006 Sep;36(9):654-62<br />
39. Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement<br />
therapy improves function of C-, A<strong>de</strong>lta-, and Abeta-nerve fibers in <strong>Fabry</strong><br />
neuropathy. Neurology. 2004;62:1066-72.<br />
40. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced<br />
cerebral blood flow velocity and impaired cerebral autoregulation in patients<br />
with <strong>Fabry</strong> disease. J Neurol 2004: 251; 564-70.<br />
41. Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of alphagalactosidase<br />
A infusions for treatment of <strong>Fabry</strong> disease. Genet Med.<br />
2003;5:144-53.<br />
42. In<strong>de</strong>rbitzin D, Avital I, Largia<strong>de</strong>r F, Vogt B, Candinas D. Kidney<br />
transplantation improves survival and is indicated in <strong>Fabry</strong>’s disease.<br />
Transplant Proc. 2005;37:4211-4.<br />
43. Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra<br />
C, Miebach E, Beck M. Electrocardiographic signs of hypertrophy in <strong>Fabry</strong><br />
disease-associated hypertrophyc cardiomyopathy. Acta Paediatr 2002;suppl<br />
439:21-7<br />
44. Kanekura T, Fukushige T, Kanda A, Tsuyama S, Murata F, Sakuraba H,<br />
Kanzaki T. Immunoelectron-microscopic <strong>de</strong>tection of globotriaosylcerami<strong>de</strong><br />
accumulated in the skin of patients with <strong>Fabry</strong> disease. Br J Dermatol.<br />
2005;153:544-8<br />
45. Kolodny EH, Pastores GM. An<strong>de</strong>rson-<strong>Fabry</strong> disease: Extrarenal,<br />
Neurologic Manifestations. J Am Soc Nephrol 2002; 13: 150-153.<br />
46. Lao LM, Kumakiri M, Mima H, Kuwahara H, Ishida H, Ishiguro K, et al. The<br />
ultrastructural characteristics of eccrine sweat glands in a <strong>Fabry</strong> disease<br />
patient with hypohidrosis. J Dermatol. Sci. 1998; 18: 109-117.<br />
47. Larral<strong>de</strong> M, Boggio P, Amartino H, Chamoles N. <strong>Fabry</strong> disease: a study of 6<br />
hemizygous men and 5 heterozygous women with emphasis on <strong>de</strong>rmatologic<br />
13